XFOR (X4 Pharmaceuticals) Shiller PE Ratio: (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XFOR X4 Pharmaceuticals Inc XFOR
24 GF Score
Price $4.29
! 6 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


X4 Pharmaceuticals  (NAS:XFOR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


X4 Pharmaceuticals Shiller PE Ratio Related Terms


X4 Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Shiller PE Ratio Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

X4 Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XFOR vs DMAC, IKT, LXEO: Shiller PE Ratio Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X4 Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Shiller PE Ratio falls into.


XFOR
24GF Score
X4 Pharmaceuticals Inc XFOR
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

X4 Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, X4 Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.13/333.9520*333.9520
=-0.130

Current CPI (Jun. 2026) = 333.9520.

X4 Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201512 0.000 236.525 0.000
201612 -172.211 241.432 -238.205
201703 -174.312 243.801 -238.768
201706 -184.851 244.955 -252.011
201709 -193.255 246.819 -261.479
201712 -302.399 246.524 -409.643
201803 -133.200 249.554 -178.248
201806 -153.000 251.989 -202.765
201809 -136.800 252.439 -180.973
201812 -32.659 251.233 -43.412
201903 -200.100 254.202 -262.877
201906 -30.600 256.143 -39.895
201909 -36.600 256.759 -47.604
201912 -19.800 256.974 -25.731
202003 -16.800 258.115 -21.736
202006 -22.800 257.797 -29.535
202009 -26.100 260.280 -33.488
202012 -27.300 260.474 -35.001
202103 -39.000 264.877 -49.170
202106 -22.200 271.696 -27.287
202109 -22.800 274.310 -27.757
202112 -37.200 278.802 -44.559
202203 -21.600 287.504 -25.090
202206 -18.000 296.311 -20.287
202209 -7.800 296.808 -8.776
202212 -8.700 296.797 -9.789
202303 -4.800 301.836 -5.311
202306 -9.900 305.109 -10.836
202309 -0.300 307.789 -0.326
202312 -2.670 306.746 -2.907
202403 -7.770 312.332 -8.308
202406 13.570 314.175 14.424
202409 -5.480 315.301 -5.804
202412 -6.000 315.605 -6.349
202503 0.040 319.799 0.042
202506 -3.470 322.561 -3.593
202509 -0.690 324.800 -0.709
202512 -0.263 324.054 -0.271
202603 -0.160 330.213 -0.162
202606 -0.130 333.952 -0.130

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score

Get the complete analysis for XFOR

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.29
Price